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The global shortage of donor corneas has garnered extensive interest in the development of graft alternatives
suitable for endothelial keratoplasty using cultivated primary human corneal endothelial cells (CECs). We
have recently described a dual media approach for the propagation of human CECs. In this work, we
characterize the effects of a Rho-kinase inhibitor Y-27632 on the cultivation of CECs propagated using the
dual media culture system. Seventy donor corneas deemed unsuitable for transplantation were procured for
this study.We assessed the use of Y-27632 for its effect at each stage of the cell culture process, specifically for
cell attachment, cell proliferation, and during both regular passaging and cryopreservation. Lastly,
comparison of donor-matched CEC-cultures expanded with or without Y-27632 was also performed. Our
results showed that Y-27632 significantly improved the attachment and proliferation of primary CECs. A
non-significant pro-survival effect was detected during regular cellular passage when CECs were pre-treated
with Y-27632, an effect that became more evident during cryopreservation. Our study showed that the
inclusion of Y-27632 was beneficial for the propagation of primary CECs expanded via the dual media
approach, and was able to increase overall cell yield by between 1.96 to 3.36 fold.
T
he human cornea is a transparent, highly refractive structure of the eye and consists of five layers. The
innermost single cell-layer is the corneal endothelium (CE), which plays a major role in the dynamic
regulation of corneal hydration between its ‘leaky’ barrier and active fluid pumps1–4. In the eye, the cells
of the corneal endothelial layer are locked in the G1-phase of cell cycle, mediated in part by tight cell-to-cell
contacts5, as well as the presence of anti-proliferative factors such as transforming growth factor (TGF)-b2, found
within the aqueous humor6. The non-proliferative state of the humanCE in vivo prevents functional regeneration
of damaged corneal endothelial cells (CECs). Hence, any loss of CECs results in the cellular enlargement of
surviving adjacent CECs (polymegathism) tomaintain functional integrity1. However, when extensive cell-loss of
the CE layer occurs beyond a certain threshold such that the functional capacity of the remaining CECs becomes
compromised, corneal decompensation will occur. This results in cornea edema that will eventually lead to
corneal blindness1. Such phenomenon is often seen in patients afflicted by corneal endothelial dystrophies such
as Fuchs’ dystrophy7,8 or Congenital Hereditary Endothelial Dystrophy9,10.
Currently, restoring the vision of patients affected by these visually debilitating conditions can be achieved
through surgical intervention. While a variety of surgical techniques have been developed11,12, including proce-
dures that utilize all components of a donor cornea for treatments in multiple patients13, as well as the possibility
of using alternative approaches instead of allograft corneal transplantation surgery in suitable patients14, con-
ventional corneal transplants are still greatly limited by the availability of donor graft material1. This is a global
problem that is further impeded by amyriad of factors, e.g. cultural restrictions to donation, that will in oneway or
another tap into the pool of donor corneas available1. Therefore, alternative approaches able to ease the surgical
bottleneck are of great clinical interests. Currently, two potential alternatives are being explored. The first, ‘cell-
injection therapy’, involves the direct injection of cultivated corneal endothelial cells into the anterior chamber of
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cell-tissue engineering of graft alternatives suitable for endothelial
keratoplasty using cultivated cells grown or seeded on either a bio-
logical or synthetic scaffold carrier17–19. If successful, donor corneas,
even those rejected for transplant due to low corneal endothelial cell
counts20,21, can be set aside for cellular expansion for these alternative
approaches. This however, requires the capacity to propagate human
CECs in an in vitro setting.
Reports of humanCEC-cultures were described as early as 1977 by
Baum and colleagues22. At that time, difficulties were encountered in
the propagation of CECs from donors over the age of 20, where
confluence of culture took approximately 8 to 9 weeks to achieve
and cellular morphology was heterogenic with evidence of CECs
becoming multi-nucleated22. Since then, many reports of human
CEC-culture have surfaced, some with more apparent success than
others1. Many subtle changes have been made to improve human
CEC-cultures over the years. For example, Shima and colleagues
reported that using L-ascorbic acid 2-phosphate protected cultivated
CECs against oxidative DNA damage and significantly increased the
proliferation of human CECs through the up-regulation of hepato-
cyte growth factor (HGF) via a HGF/c-Met autocrine loop23,24. The
selective activation of p120-catenin-Kaiso signaling to disrupt con-
tact inhibition of CECs, bypassing canonical Wnt/b-catenin signal-
ing, was able to prevent epithelial-to-mesenchymal-like transition
(EMT) of expanded CECs25. The direct inhibition of TGF-b signaling
using SB431542 and the use of bone morphogenetic protein-7 to
inhibit TGF-b-mediated EMT has also been reported to prevent
the fibroblastic transformation of expanded CECs26.
Small GTPase Rho and its downstream effectors, the Rho-assoc-
iated coiled-coil protein kinases (ROCK), are associated with a range
of cellular functions such as actin cytoskeleton organization, cell
adhesion, G1-S progression of cell cycle, cytokinesis, and apopto-
sis27,28. The compound Y-27632, [(1)-(R)-trans-4-(1-aminoethyl)-
N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride], has
been reported to be a selective ROCK inhibitor (ROCKi) of
p160ROCK29, and has been shown to inhibit apoptosis, and increase
cellular attachment and proliferation of both primate and human
CECs30,31. However, Pipparelli and colleagues recently reported that
inhibition of Rho-ROCK activity did not induce proliferation of
human CECs, questioning the use of Y-27632 and its relevance in
enhancing the proliferation rates of human CECs32.
We have recently described the propagation of humanCECs using
a dual media culture system33. The aim of this study was to system-
atically investigate the effects of ROCKi Y-27632 on the adherence,
cell proliferation and cellular survival, for both regularly sub-cul-
tured and cryopreserved cells, when applied during in vitro expan-
sion of human CECs grown using the dual media approach. The
incorporation of ROCKi into the isolation and propagation of
CECs for three passages were also assessed.
Results
Characterization of human CECs and their exposure to Y-27632.
Primary human CECs were propagated using the dual media approach
as depicted in the schematic (Fig. 1A). Isolated CECs grown using the
dual media approach consistently generated a confluent homogenous
monolayer of human CECs (Fig. 1B), and expressed characteristic
pump-associated NA1/K1-ATPase (Fig. 1C), tight junction protein
ZO-1 (Fig. 1D), heparin sulfate proteoglycan GPC-4 (Fig. 1E) and
cell-membrane glycoprotein CD-200 (Fig. 1F), indicative of corneal
endothelial cells34. To determine the optimal concentration of Y-
27632 to be used in this study, we performed a cell impedance-based
assay following the exposure of CECs to various concentrations of Y-
27632. Concentrations of 30 mM and above showed a significant drop
in the cellular impedance of CECs, following a 24-hours exposure, in a
dose dependent manner (Fig. 2A). Interestingly, total withdrawal of
ROCKi resulted in substantial recovery of impedance values across all
ROCKi concentrations when assessed five days after withdrawal
(Fig. 2B). Representative time-lapse micrographs showed a significant
change in cell polarity of CECs when treated with 1 mM of Y-27632
compared to donor-matched control cells treated with 10 mM of Y-
27632. However, upon withdrawal of Y-27632, cellular morphology of
CECs reverted back to their initial state (Fig 2C). From this point
onwards, a concentration of 10 mM of Y-27632 was used for the rest
of this study.
Y-27632 improves adherence and overall cell yield of human
CECs. The adherence of human CECs onto FNC-coated cell-
culture plates was assessed following the seeding of passaged cells
(P1 or P2 cells) in M5-Endo medium with or without Y-27632. The
cell attachment profiles of sub-cultured CECs were significantly
better when Y-27632 was supplemented in M5-Endo medium
during the attachment phase, as gauged by cell impedance readings
taken from the xCELLigence system at the fourth hour following cell-
seeding (Fig. 2D).
In a series of follow up experiments, we subjected freshly isolated
human CECs from independent paired donor corneas, and divided
them equally into cultures with or without the addition of Y-27632.
As expected, cells in both conditions were seen to adhere well by the
forth hour, and were able to form a homogenous monolayer with
distinct polygonal/hexagonal morphology when they reached con-
fluence (Fig. 2E and 2F). Interestingly, in these culture conditions,
CECs grown in the presence of Y-27632 consistently yielded more
CECs (between 1.86 fold to 6.07 fold more) for the 5 paired donors
assessed (Fig. 2G). Morphometric analyses of cell size, cell circularity
and coefficient of variance between donor matched-CECs samples
grown with or without Y-27632 showed significant differences in the
sizes of CECs measured (Fig. 2H). It was evident that CECs grown in
the presence of Y-27632 were significantly smaller in size (880.21 6
239.95 mm2) compared to donor-matched control cultures (1232.58
6 143.35 mm2). No significant difference was observed for overall
cell circularity and coefficient of variance between the two donor
matched-CECs populations.
Y-27632 enhances cell proliferation of human CECs in cells
isolated from young donors. The proliferation rates of human
CECs were assessed following the switch from the initial M5-
Endo medium into M4-F99 medium to initiate cellular proliferation.
The proliferation rates were evaluated by 24-hours Click-iT EdU
incorporation via immunofluorescence (Fig. 3A), and 48-hours BrdU
incorporation using flow cytometric analysis (Fig. 3B). Results from
Click-iT EdU incorporation assay showed that CECs expanded in
medium containing Y-27632 contained more proliferative cells than
their respective donor-matched controls grown in the same medium
without Y-27632 (Fig. 3A). Although an increase in cell proliferation
was detected across all donor samples, CECs from some donors
showed a greater proliferative response when exposed to Y-27632
than others. Overall, the percentages of proliferative increase
detected by EdU incorporation in the presence of Y-27632 were
0.96%, 1.54%, 2.62%, 4.91%, and 6.00% over a period of 24 hours
(n 5 5; Table 1). Results from flow analysis of 48-hours BrdU
incorporation corroborated the above results, showing significant
increase of CECs proliferation of 4.46%, 8.72% and 10.54%
detected in the samples expanded in the presence of Y-27632 (n 5
3; Table 1). Interestingly, when this study was repeated in human
CECs isolated from older donors aged 60 and above, proliferative
enhancement seen in younger donors were not detected in older
samples cultured in Y-26732, and no statistical significance were
detected (Supplementary Table 1).
Y-27632 did not significantly improve the viability of human
CECs during regular cellular passage or cryopreservation. To
study the effect of Y-27632 on the viability of human CECs during
regular cellular passage, cells were pre-treated with Y-27632 at least
1 hour prior to cellular dissociation. The live-dead assay was
www.nature.com/scientificreports
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immediately performed and analyzed by flow cytometer for total
percentage live cells. During regular cellular passage, flow analysis (n
5 6) showed that 89.52%6 6.89% of the control CECs remained viable.
Comparatively, donor-matched CECs pre-treated with Y-27632 showed
90.72% 6 6.35% in cell viability. These results suggested that the pre-
treatment of Y-27632 did not confer any significant advantage to the
survival of CECs during cellular passage (Fig. 4A). The live-dead assay
was also conducted on cryopreserved CECs (n 5 6). In the control
group, approximately 63.96%6 10.02% of CECs survived the process of
cryopreservation. Donor-matched CECs that were exposed to Y-27632
were found to have survived better with 70.45% 6 10.35% of the cells
that remained viable (Fig. 4B). However, the fractional increase in
overall cell viability of approximately 6.49% 6 14.36% observed in
cryopreserved CECs pre-treated with Y-27632 were not statistically
significant. Nevertheless, when the cryopreserved groups of control
CECs (Fig. 4C and 4C9) and Y-27632 pre-treated CECs (Fig. 4D and
4D9) were thawed out and seeded at a physiological density of 3,000
cells per mm2, both group of cells were successfully revived, and formed
compact homogeneous polygonal/hexagonal cell layers following seven
days of culture in M5-Endo medium.
The use of Y-27632 is beneficial for the cellular expansion of
human CECs. The final comparative study was performed using 4
pairs of donor-matched human CECs isolated and expanded to the
second passage with or without Y-26732 added throughout the
culture period. Result obtained showed that there were a marked
increase in the overall cell-yield when Y-26732 is added, ranging
from 1.96, 2.54, 2.67, and 3.36 folds (Table 2).
Discussion
The isolation and propagation of primary human CECs has been
described by various research groups using different approaches
revolving around the use of a single basal medium, each supplemen-
ted with different additives23–26,32,35. However, most of these reports
were not extensively characterized. We recently described the pro-
pagation of CECs via a dual media approach33. In that study, the
isolated CECs were first established in M5-Endo medium overnight.
Subsequently, the M5-Endo-stabilized CECs were propagated in a
proliferative M4-F99 medium for their expansion until the CECs
reached confluence, at which point the culture mediumwas switched
back toM5-Endo medium. The incorporation of the M5-Endomed-
ium, as depicted (Fig. 1A), was found to be effective in preventing
potential endothelial-to-mesenchymal-like transition of the expanded
CECs33. Indeed, the unique cellular morphology of human CECs
(Fig. 1B), along with the expression of various markers indicative of
the human corneal endothelium, such as the pump-associated NA1/
K1-ATPase, tight junction protein ZO-1, heparin sulfate proteoglycan
GPC-4, and cell-membrane glycoprotein CD-200, could be main-
tained (Fig. 1C–1F) by CECs expanded using this approach.
Primary CECs propagated using the dual media approach have been
characterized to the third passage, potentially generating between 1 3
107 to 2.5 3 107 CECs from a pair of donor corneas33,36. Although the
dual media approach of propagating human CECs is relatively robust,
the cultures of these primary cells are not without their limitations,
and can be affected substantially by the procurement process as well as
donor variations37,38. It should be noted that all the donor corneal pairs
procured from Lions Eye Institute for Transplant and Research were
processed within 14 days of preservation to minimize potential vari-
ation38. The successful establishment of a confluent culture of P0
human CECs is partly dependent on the final cellular yield of the
isolated primary CECs, and their capacity to proliferate in M4-F99
medium, which can be potentially affected by inherent donor variation
and other external factors39. Some of these factors include the relative
health of the donor before death, the cause of death, as well as the
Figure 1 | Culture and characterization of primary human CECs. (A) Schematic diagram depicting the expansion strategy of human CECs using a dual
media approach, inter-switching between a M5-Endo medium for cellular stabilization/maintenance and a M4-F99 medium for cell proliferation. (B)
Representative micrograph of a confluent homogeneous monolayer of P0 human CECs maintained for several days in M5-Endo medium following
proliferative expansion inM4-F99 medium. Representative micrographic indirect immuno-fluorescent images of human CECs taken at the first passage
which express (C) NA1/K1-ATPase, (D) ZO-1, (E) GPC-4 and (F) CD-200, indicative of the corneal endothelium. Scale Bars – B: 100 mm; C–F: 50 mm.
www.nature.com/scientificreports
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Figure 2 | (A) Human CECs were seeded for 24 hours before exposure to various concentrations of Y-27632 (n 5 7) including 3 mM, 10 mM, 30 mM*,
100 mM**, 300 mM**, and 1000 mM** for another 24 hours and analyzed using the xCELLigence system. (B) Normalized impedance readings of CECs
treated for 24 hours, in various concentrations of Y-27632 (solid bars) and their respective recovery at Day 5 after the withdrawal of Y-27632 at Day 2
(striped bars). Cell index was normalized to 1 (dotted line) to untreated controls at 24 hours and at Day 5. (C) Representative time-lapse micrographs of
CECs at start state, before the addition of Y-27632; 1 hour and 24 hours after the addition of Y-27632; and 24 hours after Y-27632 withdrawal. Either
10 mM(top panel) or 1 mM (bottom panel) of Y-27632 was used. (D) Impedance readings of CECs adherence at 4 hours, with or without the presence of
10mM of Y-27632 (n 5 4) were measured using xCELLigence. Representative phase-contrast micrographs showing the morphology of CECs at 4 hours
following cellular attachment (left panel) and at confluence (right panel), with insert showing a higher magnification of the confluent culture of
(E) normal control P0CECs and (F) their donor-matched counterparts whichwere exposed to 10 mMof Y-27632 throughout culture. (G)Overall cellular
yield of isolated donor-matched P0 CECs growth to confluence with or without exposure to 10 mMof Y-27632. (H)Morphometric analysis (n5 3) – cell
size*, cell circularity and coefficient of variance – of confluent donor-matched P0 human CECs grown with or without any exposure to 10 mMY-27632
(*p , 0.05 and **p , 0.01) – For (D) and (H), ‘C’ denote control; ‘Y’ denote Y-27632 treated. Scale Bars: 100mm.
www.nature.com/scientificreports
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duration from death to enucleation and preservation and the time
from preservation to the establishment of culture1,40. Beyond these
potential hindrances, we report herein that the dual media approach
in expansion of human CECs can be further enhanced, in terms of
absolute cellular yield, simply by the treatment of the cultured CECs
with the well-described Rho-kinase inhibitor Y-2763229.
It is well established that the Rho-kinases are protein serine/threo-
nine kinases that have pleiotropic functions, which include the
regulation of cellular contraction, growth, migration, metabolism,
polarity, as well as apoptosis27,28,32,41–43. In this study, three specific
outcomes of ROCK inhibition using Y-27632 were assessed within
the context of primary human CECs cultured using the dual media
approach described33. These include cell-substrate adhesion; cellular
proliferation, and general cell survival during regular cell passage, as
well as cryopreservation. Even though it has been shown by various
groups that a concentration of between 10 mM and 30 mM of Y-
27632 can be used for the culture of human CECs32,44, and up to
100 mM of Y-27632 can be used without significant detrimental
effect for the culture of primate CECs30, our results showed a dose-
dependent drop in the adhesion strength when CECs were exposed
to more than 30 mM of Y-27632 (Fig. 2A). This is not surprising, as
ROCK is known to regulate cellular homeostasis27,43, and its inhibi-
tion has been associated with changes in actin stress fibers, as well as
focal adhesion45, which in turn may affect adhesion strength. Similar
occurrence has been observed in primary cell cultures of human
trabecular meshwork (HTM) and Schlemm’s canal (SC), where
inhibition of Rho kinase by Y-27632 lead to reversible changes in
cell shape, and actomyosin re-organization45. Indeed, time-lapse
micrographs showed that the polarity of CECs was evidently affected
by the higher dosage of Y-27632, and upon withdrawal, substantial
recovery was observed, which coincided with the impedance read-
ings of the cells (Fig. 2B). Taken together, these results suggested that
concentrations above 30 mM of Y-27632 affect the attachment
strength of CECs in a dose-dependentmanner. It has been postulated
that cellular relaxation and the loss of cell-substratum adhesion
brought on by Rho kinase inhibition resulted from the decrease in
myosin light-chain phosphorylation, inHTMand SC cells45, through
the dephosphorylation ofmyosin light chain phosphatase complex46.
However, it should be noted that the two studies used lower concen-
trations of Y-27632, 5 mM and 10 mM, as well as different cell
types45,46. Hence, future studies on the phosphorylation state of myo-
sin light-chain in primary human CECs measured in the presence of
Figure 3 | Exposure to Y-27632 increases the proliferation rates of primary human CECs. (A) Click-iT EdU assay was carried out to assess the cell
proliferation of human CECs in M4-F99 medium with or without addition of 10 mM Y-27632 over a period of 24 hours (n 5 5; *p , 0.05). (B)
Representative flow cytometric dot plots of BrdU incorporation of human CECs grown inM4-F99medium with or without exposure to 10 mMY-27632
over a period of 48 hours (n 5 4; *p , 0.05). Scale Bars: 100 mm.
Table 1 | Proliferation rates of human CECs with and without Y-27632
Donor M4-F99 Medium (Control) M4-F99 Medium (Y-27632) Overall increase
Click-iT EdU incorporation for 24 hours
08 3.43% 6.05% 2.62%
09 18.75% 19.71% 0.96%
10 13.27% 18.18% 4.91%
17 7.69% 13.69% 6.00%
23 12.74% 14.29% 1.54%
BrdU incorporation for 48 hours
19 35.42% 45.96% 10.54%
20 24.37% 28.83% 4.46%
21 47.53% 56.25% 8.72%
In the presence of Y-27632, an increase of approximately 0.96% to 6.00% of proliferating primary human CECs were observed when assessed after 24 hours click-iT EdU incorporation, and an increase of
approximately 4.46% to 10.54% were detected when assessed after 48 hours BrdU incorporation.
www.nature.com/scientificreports
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different concentration of Y-27632 will enable better understanding
of the loss of adhesion strength observed in the present study.
The cellular adhesion of CECs to the extracellular matrix (ECM)
substratum is an important parameter for the successful propagation
of CECs. Although we and others have shown that CECs can be
established directly onto uncoated cell-culture vessels, the seeding of
CECs onto culture wares pre-coated with ECM such as FNC coating
mixture, collagen type-I, collagen type-IV or laminin-5 significantly
increases the attachment of CECs35,38,47,48. In this study, our results
clearly showed that addition of Y-27632 during cell seeding further
improved cell attachment of CECs on FNC-coated cell-culture plates
by 38% 6 13% when impedance measurements were taken at the
fourth hour (Fig. 2B). This finding is in line with previous reports
that showed a significant increase in cellular adhesion of human CECs
cultured with Y-2763232,44. Similar findings have been shown in the
adhesion of primate CECs, where the inhibition of actin polymeriza-
tion and up-regulation of vinculin were associated with the enhanced
cell attachment in Y-27632 treated monkey CECs49. Rho and ROCK
are known to regulate cell adhesion by enhancement of acto-myosin
contractility43. Whilst it has been postulated that the RhoA-ROCK-
PTEN signaling pathway may be integral to the reported findings49,50,
further investigation is required to better understand the role of Y-
27632 and the complex signaling mechanisms involved that resulted
in the enhancement to the attachment of human CECs.
In a series of experiments, we found that freshly isolated donor-
matched primary CECs, grown with or without the presence of
Y-27632, adhered and proliferated well in the dual media culture
system. Interestingly, CEC-populations exposed to Y-27632 generally
reached confluence within a shorter period of time (unpublished
observation), consistently yielded more CECs, and were remarkably
more compact in cell-size (Fig. 2C–2F). The shorter time it took
for CEC-cultures to reach confluence was most likely due to the
increased proliferation rates as shown in CEC-cultures propagated
in M4-F99 medium supplemented with Y-27632 (Fig. 3A and 3B).
This observation is consistent with various reports showing increased
cell proliferation of human CECs31,44, primate CECs30, and bovine
CECs51 when Y-27632 was added to the culture medium. It has been
demonstrated, at least in primate CECs, that PI-3-kinase signal cas-
cade activated by Y-27632 resulted in the up-regulation of cyclin D
and down-regulation of p27, which is central to the proliferation of
CECs31. It should be noted that the use of Y-27632 to increase the
proliferation of human CECs may only be appropriate for cultures of
CECs established using younger donors, as the addition of Y-27632
were not found to be advantageous for cultures established using older
donors (Supplementary Table 1). This is not surprising as similar
observation was previously reported by Pipparelli and colleagues that
Y-27632 has no effect on the proliferative capacities on human CECs
in their study, which utilized corneas from donor aged 73 6 3 years32.
It has been widely reported that human CECs isolated from older
donors were less proliferative than those established from younger
donors, and this has been associated to significant increase of cyclin
kinase inhibitors p16INK4a and p21WAF1/Cip1, hence resulting in an age-
dependent increase in negative regulation of cell cycle52.
There is a myriad of studies that have shown the involvement of
ROCK signaling in the regulation of both pro-apoptotic signals, and
anti-apoptotic or cell survival signals27,43. The dichotomy of the res-
ponses is believed to be stimulus and cell type-dependent53. For
example, high intensity ROCK activity in cells placed under extended
or elevated stressful conditionsmay contribute to the initiation of the
apoptotic cascade, amplifying or even accelerating the apoptotic
Figure 4 | The use of Y-27632 for cell survival during regular cellular passage and recovery from cryo-preservation. (A) Confluent cultures of CECs
maintained inM5-Endo medium, with or without a 1-hour pre-treatment of 10 mMY-27632 were analyzed for overall percentage of live cells, as gauged
by the Annexin V detection kit, following regular cellular passage - ‘C’ denote control; ‘Y’ denote Y-27632 treated (n5 6). (B) Overall percentage live cells
were also assessed for both groups of cryo-preserved CECs that were either untreated or those that were exposed to 10 mMY-27632 - ‘C’ denote control;
‘Y’ denote Y-27632 treated (n5 6). Representative micrographs of (C) cryo-preserved control or untreated CECs and (D) corresponding CECs that were
exposed to 10 mMY-27632 that were thawed out and seeded at physiological density of approximately 3,000 cells per mm2. (C9) and (D9) depicts CECs
from correspondingmicrographs (C) and (D) that were briefly treated with TrypLE Express for 5 seconds to better visualize the CECs. Scale Bars: 50 mm.
Table 2 | Human CECs expansion profile with and without the presence of Y-27632
Donor OD Control @ P2 OS ROCKi @ P2 Fold Increase
17 260,000 510,000 1.96
22 1,845,000 4,680,000 2.54
23 617,000 2,070,000 3.36
24 708,000 1,890,000 2.67
Expansion profiles of primary human CECs propagated to the second passage were compared. Estimated cell-yield of CECs expanded using the dual media approach as control (OD) was compared to
donor-matched CECs grown in the dual media approach supplemented with Y-27632 throughout the study (OS). An increase of at least 1.96 fold and up to 3.36 fold was observed in studies conducted
using CECs isolated from 4 independent donors.
www.nature.com/scientificreports
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process; and under such situations, inhibition of ROCK signaling
may produce a pro-survival outcome41. Indeed, it has been shown
that the use of Y-27632 is effective in counteracting apoptosis in
human embryonic stem cells, and it greatly improved the efficiency
of clonal expansion of human embryonic stem cells54, as well as in the
cryopreservation of human embryonic stem cells55,56. Cell survival of
cultured primary primate CECs were also found to improve in the
presence of Y-2763230. However, we did not detect any improvement
to the overall cell survival of humanCECswhen passaged (Fig. 4A) or
cryopreserved (Fig. 4B) in the presence of Y-27632 over donor-
matched control cells. We speculate that these results may be in part
due to the dual media culture system, specifically theM5-Endomed-
ium that the human CECs were maintained in before they were
passaged or cryopreserved. We have previously shown, by microar-
ray analysis, that there were significant gene expression changes in
the cultivated human CECs following the switch fromM4-F99 med-
ium to M5-Endo medium33. These changes may have conferred a
protective effect on the cells that were maintained in M5-Endo med-
ium. More importantly, human CECs expanded using the dual
media approach can be cryopreserved, and subsequently revived
with or without the use of Y-27632, to form a homogenous mono-
layer of polygonal CECs (Fig. 4C and Fig. 4D).
Taken together, results from this study as well as others32,44 -
including studies using primate CECs30,49 indicate that the inhibition
of ROCK signaling pathway using Y-27632 evidently influenced the
propagation of primary CECs in a positive manner. It has since been
demonstrated by Okumura and colleagues that the mechanistic
actions of Y-27632 in promoting the proliferation of primary human
CECs involve both cyclin D – a positive G1 regulator; as well as p27 –
a negative G1 regulator, via PI 3-kinase signaling31. However, it
should be noted that although Y-27632 has been touted as a selective
inhibitor of ROCK29, it is known to inhibit other kinases such as
citron kinase43,57. As such, further studies should aim at elucidating
the exact interaction of Y-27632 within ROCK signaling, and if other
ROCKi similar to Y-27632 such as Y-3014158 have similar effects
when supplemented into the culture of primary CECs. Indeed, it
has been shown that Y-39983, a molecule derived from Y-27632,
but with higher potency in the inhibition of ROCK activity59 has
shown some promise in increasing the proliferation of primate and
human CECs31.
In conclusion, this study clearly showed that incorporating Y-
27632 into the dual media culture approach of expanding primary
human CECs is beneficial for the propagation of these primary cells,
specifically CECs that were isolated from younger donors (below 40).
The inclusion of Y-27632 into the respective media during the
attachment phase (M5-Endo medium) and proliferative phase
(M4-F99 medium) resulted in a 1.96 fold to 3.36 fold increase in
overall cell yield by the second passage through the enhancement
Table 3 | Donor information
Serial Number Age Sex Days to Culture Cell Count (OS/OD) Cause of Death
F T
1 2 3 4 3 4
01 18 M 8 2907/3040 Motor Vehicle Accident N N
02 39 F 9 3125/2882 Anoxia N
03 32 M 7 3021/2427 Sepsis N N
04 27 F 6 2203/2037 Sepsis N
05 17 F 6 3058/3185 Motor Vehicle Accident N N
06 20 M 14 3584/3704 Myocardial Infarction N
07 11 F 7 3534/3584 Anoxia N N
08 35 F 5 2899/2941 Overdose N N N
09 31 F 9 2591/2611 Overdose N N N
10 19 F 7 2681/2882 Acute Cardiac Crisis N N N
11 3 F 5 3650/3690 Drowning N N
12 15 F 6 2778/2770 Anoxia N N
13 22 M 11 2604/2950 Possible Overdose N N
14 18 F 14 3922/3953 Myocardial Infarction N N
15 19 M 10 2890/2703 Leukemia N N
16 19 M 10 3175/3067 Motor Vehicle Accident N N
17 28 F 7 2778/2857 Myocardial Infarction N N N
18 21 M 8 3322/3030 Motor Vehicle Accident N
19 20 M 11 3876/3663 Anoxia N
20 35 M 10 3115/2857 Overdose N
21 38 F 5 3356/3425 Acute Cardiac Crisis N
22 19 M 10 2717/2577 End Stage Lung Disease N
23 21 M 6 2890/2974 Leukemia N N N
24 35 F 10 2268/2331 Sepsis N
25 9 M 10 3247/3096 Anoxia N N
26 3 M 9 3968/4082 Drowning N N
27 23 M 5 3311/3413 Motor Vehicle Accident N
28 20 F 9 3472/3300 Overdose N
29 14 F 5 3115/3205 Cerebral Edema N
30 9 M 10 3846/3774 Total Heart Block N
31 35 M 8 2632/2770 Pneumonia N
32 33 M 11 2404/2584 Gun Shot Wound N
33 31 M 5 2747/2525 Motor Vehicle Accident N
Donor age ranged from 3 year-old to 39 year-old with a median age of 20 year old. Days taken from death of donor to the initiation of corneal endothelial cell culture ranged from 5 days to 14 days with a
median of 8 days. Corneal endothelial cell counts of corneas procured were over 2,000 per mm2. Data points generated in this study from cultures of human CECs that contributed to the respective figures
and tables were denoted by ‘N’. OS: oculus sinister; OD: oculus dexter; F: Figure; T: Table.
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of cellular adherence, and increased cell proliferation (Table 2). We
have projected, in a recent report, that approximately 30 tissue-engi-
neered constructs can be generated fromCECs isolated from a pair of
donor corneas grown to the second passage using the dual media
approach60. Hence, by adding Y-27632 into the dual media culture
system, the increase in overall yield of CECs obtainable from a pair of
donor cornea could potentially generate two to three times more
tissue-engineered constructs. Hence, this can potentially increase
the supply of transplantable graft materials, whilst substantially
decreasing the costs of tissue-engineered endothelial constructs,
making such intervention available to a wider group of patients60.
Methods
Materials. Ham’s F12, Medium 199, Human Endothelial-SFM, fetal bovine serum
(FBS), Dulbecco’s Phosphate-Buffered Saline (PBS), Insulin/Transferrin/Selenium
(ITS), TrypLETM Express (TE), gentamicin, amphotericin B, Fix and Perm (Medium
A), 5-ethynyl-29-deoxyuridine (EdU) incorporation Click-iT Alexa Fluor 488 cell
proliferation assay kit, penicillin and streptomycin were purchased from Life
Technologies (Carlsbad, CA, USA). Dimethyl Sulfoxide (DMSO), ROCKi Y-27632,
trypan blue (0.4%), paraformaldehyde (PFA) and ascorbic acid were purchased from
Sigma (St. Louis, MO, USA). Basic fibroblast growth factor was bought from R&D
Systems (Minneapolis, MN, USA). FNC coating mixture was obtained from United
States Biologicals (Swampscott,MA, USA). Collagenase Awas purchased fromRoche
(Mannhein, Germany).
Research-grade human corneoscleral tissues. All research-grade human cadaver
corneal tissue procured for this study through Lions Eye Institute for Transplant and
Research (Tampa, FL, USA) were obtained with written consent from the next of kin,
and adhered to the principles outlined in the Declaration of Helsinki. A total of 33
pairs of donor corneal tissues ranged from 3 to 39 years old (Table 3) and four single
donor conreal tissue between 60 and 66 years old (Table 4) with endothelial cell count
of at least 2,000 cells per mm2 deemed unsuitable for transplantation were used for
this study. Corneoscleral tissues were preserved in Optisol-GS (Bausch & Lomb,
Rochester, NY, USA) at 4uC until they were processed, usually within 14 days of
preservation.
Cell Culture.HumanCECs from paired donor corneas were isolated using a two-step
‘peel and digest’ method38, and propagated using the dual media approach as
described33, with some modifications to evaluate the effect of Y-27632. Briefly,
isolated CECs were first established in cornea endothelial maintenance/stabilization
medium (M5-Endo; Human Endothelial-SFM supplemented with 5% FBS)
overnight. Subsequently, CECs were cultured in corneal endothelial proliferation
medium (M4-F99; Ham’s F12/M199, 5% FBS, 20 mg/ml ascorbic acid, 13 ITS, and
10 ng/ml bFGF) to promote the proliferation of human CECs33. Once CECs become
80%–90% confluent, M5-Endo was re-introduced to the culture for at least two days
before being sub-cultured via TE dissociation. Dissociated CECs were plated at a
seeding density of at least 1 3 104 cells per cm2 on FNC-coated surfaces for cellular
expansion36. All cultures were incubated in a humidified atmosphere at 37uC and 5%
CO2.
Immunocytochemistry. Confluent P2 human CECs were passaged and plated at a
density of at least 2,000 cells per mm2 on FNC-coated glass coverslips andmaintained
for approximately seven days in M5-Endo before fixation with the appropriate
fixative (Table 5). Samples were rinsed and blocked in 5% normal goat serum in PBS
for 30 min at room temperature. Subsequently, samples were incubated with the
primary antibodies at room temperature for 1 hour or at 4uC overnight. Primary
antibodies used in this study are as listed in Table 5. The samples were then washed
twice with PBS, 5 min each, and labeled with AlexaFluor 488 conjugated goat anti-
mouse IgG secondary antibody (2.5 mg/ml, Life Technology) for 1 hour at room
temperature in the dark. After two brief PBS washes, samples were mounted in
Vectashield containing DAPI (Vector Laboratories, Burlingame, CA, USA), and
visualized under a fluorescence microscope.
Characterization of Y-27632 concentrations and cell adhesion assay. To determine
the optimal concentration of Y-27632 for cultivated humanCECs, expanded P2 or P3
human CECs were seeded at a density of 2.5 3 104 cells per cm2 in each well of an E-
Plate 96 (ACEA Biosciences, San Diego, CA, USA), and cultured for 24 hours in M5-
Endo. On the second day, CECs were exposed to M5-Endo containing different
concentrations (3, 10, 30, 100, 300, and 1000 mM) of Y-27632 for another 24 hours.
Subsequently, Y-27632 was withdrawn and CECs were cultured for another five days
in fresh M5-Endo medium. The electrical impedance readings of the cells were
recorded using the xCELLigence real time cell analyzer (ACEA Biosciences)
throughout the experiment. To document the morphology of CECs exposed to
10 mMand 1000 mMof Y-27632, time-lapse images were acquired using an IncuCyte
ZOOM live cell imager (Essen BioScience, Ann Arbor, MI, USA). Viewing areas were
randomly selected and images were captured at 30-minute intervals. To assess the
effect of Y-27632 on the adherence of human CECs, P2 or P3 cells were dissociated
using TE and seeded into E-Plate 96 as described above, with or without the presence
of 10 mMof Y-27632 in M5-Endo. The seeded human CECs were equilibrated for 30
minutes in the incubator before the impedance reading depicting the adherence
profile of the CECs were captured for 24 hours.
Cell proliferation assay. Click-iT EdU Assay: Proliferation rates of human CECs
propagated with or without Y-27632 were assessed using the EdU incorporation
Click-iT cell proliferation assay as per manufacturer’s instructions. Briefly, cultured
CECs passaged using TE were seeded onto FNC-coated glass slides at a density of 53
103 cells per cm2 and maintained in M5-Endo for 24 hours. On the second day, the
medium was switched to either M4-F99 or M4-F99 containing 10 mM of Y-27632,
and cells were cultured for another 24 hours. On the third day, cells were incubated in
M4-F99 containing 10 mMof EdU for another 24 hours. Subsequently, samples were
rinsed once with PBS followed by fixation with freshly prepared 4% PFA for 15 mins,
on ice. Samples were rinsed twice with PBS, followed by incubation in 0.1% Triton X-
100 in 3% BSA in PBS for 20 minutes at room temperature for blocking and
permeabilization. Incorporated EdU was detected by fluorescent-azide coupling
Click-iT reaction where samples were incubated for 30 minutes in a reaction mixture
containing 13 Click-iT EdU reaction buffer, CuSO4, and azide-conjugated Alexa
Fluor 488 dye, in the dark. Samples were rinsed with PBS andmounted in Vectashield
containing DAPI. A Zeiss Axioplan 2 fluorescencemicroscope (Carl Zeiss, Germany)
Table 4 | Corneas from four older donors aged 60 and above were also procured for this study. Days taken from death of donor to the
initiation of corneal endothelial cell culture ranged from 4 days to 8 days. Corneal endothelial cell counts of corneas procured were over
2,000 per mm2
Serial Number Age Sex Days to Culture Cell Count (OS or OD) Cause of Death
34 66 M 7 2597 End Stage Renal Disease
35 65 F 6 2703 Cerebrovascular Accident
36 60 M 4 2494 Myocardial Infarction
37 65 M 8 2577 Cerebrovascular Accident
Single corneas from four older donors aged 60 and above were also procured for this study. Days taken from death of donor to the initiation of corneal endothelial cell culture ranged from 4 days to 8 days.
Corneal endothelial cell counts of corneas procured were over 2,000 per mm2. Data points generated from cultures of human CECs in this study from cultures of human CECs that contributed to the respective
figures and tables were denoted by ‘?’. OS: oculus sinister; OD: oculus dexter; F: Figure; T: Table.
Table 5 | Information of primary antibody used in this study
Antibody (Clone) Company (Catalog Number) Fixative Concentration
Na1/K1-ATPase (0.T.1) Santa Cruz (sc-71638) 100% Ethanol 5 minutes, 4uC 5 mg/mL
ZO-1 (1/ZO-1) BD Pharmingen (610966) 100% Ethanol 5 minutes, 4uC 5 mg/mL
Glypican-4 (MAFB4044) Creative Biomart (CAB-244MH) Fix and Perm (Medium A) 15 minutes, room temp. 10 mg/mL
CD-200 (MRC OX-104) BD Pharmingen (552023) 4% freshly made PFA 10 minutes, 4uC 10 mg/mL
The various primary antibodies used in this study are listed here by their clone name, the company of which the primary antibody was purchased from, with their respective catalog numbers. The different
methods of fixation and concentration used were optimized for the staining of primary human CECs.
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was used to examine the labeled proliferative cells. At least 250 nuclei were analyzed
for each experimental set.
BrdU Incorporation Assay: The effect of Y-27632 on proliferation of human CECs
was also investigated via a BrdU incorporation assay, where flow cytometric analyses
were performed using the MACSQuant Analyzer (MACS Miltenyi Biotec, Bergisch
Gladbach, Germany). Here, human CECs were plated at a density of 5 3 103 cells per
cm2 on FNC-coated cell-culture plates overnight inM5-Endo. On the second day, the
medium was switched to either M4-F99 or M4-F99 containing 10 mM of Y-27632,
together with BrdU for pulse-labeling, and cells were grown for another 48 hours. For
the analysis of BrdU labeled cells, samples were processed as per manufacturer’s
instructions, described in the FlowCellect Bivariate Cell Cycle Analysis Kit for DNA
replication. Briefly, labeled cell samples were dissociated with TE, spun down, and the
supernatant removed. Samples were then fixed using the fixation buffer for 20 min-
utes on ice, and permeabilized with the permeabilization buffer for 5 minutes on ice
before being treated with 300 mg/mL DNase I (Sigma) for 1 hour at 37uC.
Subsequently, the cells were incubated with Anti-BrdU Alexa Fluor 488 for 1 hour in
the dark on ice as indicated. Labeled cells were analyzed for BrdU incorporation using
the MACSQuant Analyzer and a minimum of 10,000 events were captured.
Cell survival assay. To assess the effect of Y-27632 on human CECs during regular
cellular passage, confluent CEC-cultures were pre-treated with Y-27632 one hour
before TE dissociation. Corresponding donor-matched control CEC-cultures were
not exposed to Y-27632. Viable and dead CECs were distinguished using Fluorescein
isothiocyanate (FITC) Annexin V apoptosis detection kit with Propidium Iodide
(BioLegend, San Diego, CA, USA) following the manufacturer’s instructions, which
enables discrimination between viable cells (Annexin V-FITC2ve/PI2ve); early
apoptotic cells (Annexin V-FITC1ve/PI2ve); and late apoptotic cells (Annexin V-
FITC1ve/PI1ve). Briefly, harvested single cells, with or without pre-treatment of Y-
27632, were re-suspended and incubated in solution containing AnnexinV-FITC and
PI, in the dark for 15 minutes, before being analyzed using a FACS Verse flow
cytometer (Becton Dickinson, East Rutherford, NJ, USA).
To evaluate the effect of Y-27632 on cryopreservation of human CECs, confluent
cells cultured with and without the 1 hour pre-treatment of Y-27632 were dissociated
via TE, centrifuged and resuspended in freezing medium consisting of 10%DMSO in
M5-Endo. A total of 53 105 cells were dispensed into each cryovial (Nalgene, Thermo
Fisher Scientific, Waltham, MA, USA), and immediately placed in a freezing con-
tainer (Nalgene) containing pre-cooled isopropyl alcohol (MerckMillipore, Billerica,
MA, USA) and transferred to a280uC freezer overnight. The following day, cryovials
were transferred and stored in liquid nitrogen. After at least one week of storage in
liquid nitrogen, cryovials were retrieved and thawed in a 37uC water bath. After the
removal of the freezing medium via centrifugation, cell pellets were resuspended and
divided, where half was placed in a solution containing Annexin V-FITC and PI and
analysed via flow cytometry as described above. The remaining CECs were seeded at a
density of 3,000 cells per mm2 and maintained in M5-Endo for at least seven days.
Statistics. All numeric data obtained were expressed as mean 6 standard deviation
(SD). All statistical analyses were performed using SPSS Statistics 22.0 (IBM, Chicago,
IL, USA). The comparison of cell impedence of human CECs exposed to various
concentrations of Y-27632 was performed using one-way ANOVA followed by post-
hoc Bonferroni test for multiple comparisons (Figure 2A). All other statistical
comparisons between non-treated human CECs (control) against donor-matched Y-
27632-treated human CECs were evaluated using paired samples t-tests. All results
with a p-value of less than 0.05 were deemed to be statistically significant.
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